Sanofi SA Price, Chart & Factor Exposure
Free Data & Analytics AccessNext earnings: Thu, Jan 28, 2027, after the market closes · estimates and history
Sanofi SA Forecast
Sanofi SA short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (7 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 24.3% a year, a typical one-standard-deviation range is 77.87–83.39 over a week, 74.98–86.28 over a month and 61.05–100.21 over a year. (Signals as of 5 Nov 2026.)
Sanofi SA Price Chart
Sanofi SA Factors
YoY +21.0%
YoY −16.7%
YoY −8.7%
YoY +0.2%
YoY −15.0%
YoY +13.7%
YoY −17.4%
YoY −9.2%
YoY +8.0%
YoY +16.8%
YoY +5.2%
YoY −7.5%
YoY +2.1%
YoY −8.3%
YoY −11.1%
Sanofi SA fundamentals: income statement, balance sheet & cash flow
Sanofi SA reported revenue of €46.72bn and net income of €7.81bn in FY2025, the year ended 31 December 2025 — revenue up 5.5% and net income up 40.5% on the prior year. Free cash flow was €8.99bn. These figures are as reported in the filings, not restated: 27 fiscal years and 98 quarters of history, back to December 1999.
| EUR billions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 46.72 | 44.29 | 41.11 | 40.30 | 39.18 |
| Cost of revenue | 13.05 | 13.20 | 12.62 | 11.87 | 12.25 |
| Gross profit | 33.67 | 31.09 | 28.49 | 28.44 | 26.92 |
| Research & development | 7.84 | 7.39 | 6.51 | 6.50 | 5.69 |
| Selling, general & admin. | — | 9.18 | — | — | — |
| Operating income | 9.60 | 14.45 | 12.98 | 13.15 | 8.13 |
| EBITDA | 12.48 | 12.46 | 12.55 | 13.49 | 11.70 |
| Interest expense | 0.63 | 0.60 | 0.52 | 0.39 | 0.36 |
| Pre-tax income | 6.02 | 6.76 | 6.12 | 9.99 | 7.84 |
| Income tax | 1.04 | 1.20 | 1.02 | 1.91 | 1.56 |
| Net income | 7.81 | 5.56 | 5.40 | 8.37 | 6.22 |
Download Sanofi SA fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.SAN.PA&statement=all&freq=a&format=csv&years=10
Figures in EUR, statements as filed. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic.
Research on Sanofi SA
Explore MacroFinance macro & markets research and analysis.
Sanofi SA Trading Strategies
9 backtested tactical asset allocation strategies hold VGK (European market), the closest tradable exposure to Sanofi SA; 1 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in VGK | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Adaptive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Defensive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Protective Asset Allocation - CPR | Moderate | Monthly | Premium · upgrade to view | |||
| Financial Mentor's Optimum3 | Moderate | Monthly | Premium · upgrade to view | |||
| Wouter Keller's Bold Asset Allocation - Balanced | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Protective Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Vigilant Asset Allocation - Balanced | Moderate | Monthly | Premium · upgrade to view | |||
| Ilya Kipnis' Defensive Adaptive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keuning and Keller's Generalized Protective Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
Statistical Distribution of Returns
PlusHow Sanofi SA’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Sanofi SA (France)
Sanofi SA is a listed security in France. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
More on Banco Santander
Frequently asked questions
What is Sanofi SA?
What is the latest Sanofi SA price?
Is Sanofi SA in an uptrend?
How volatile is Sanofi SA?
What factors affect Sanofi SA?
Which trading strategies trade Sanofi SA?
How are Sanofi SA returns analysed?
Where can I download free Sanofi SA historical data?
Free Sanofi SA historical data (last 10 years)
Browse or instantly download the last 10 years of Sanofi SA daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.SAN.PA&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 84.92 |
| 2026-11-19 | 83.79 |
| 2026-11-18 | 86.25 |
| 2026-11-17 | 86.56 |
| 2026-11-16 | 88.32 |
| 2026-11-13 | 87.6 |
| 2026-11-12 | 87.98 |
| 2026-11-11 | 86.61 |
| 2026-11-10 | 85.95 |
| 2026-11-09 | 85.76 |
About this stock
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.